Chondrosarcoma - Pipeline Review, H1 2020

May 2020 | 481 pages | ID: CCFC7A462B5EN
Global Markets Direct

Abstracts

Chondrosarcoma - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chondrosarcoma – Pipeline Review, H1 2020, provides an overview of the Chondrosarcoma (Oncology) pipeline landscape.

Chondrosarcoma is a malignant cancer whose tumor cells produce a pure hyaline cartilage that results in abnormal bone and/or cartilage growth. Signs and symptoms include pain in the affected area that may worsen at night or during physical activity, swelling in the painful area, a lump or mass, enlargement of an existing growth, limping, difficulty moving the affected limb, changes in urination. Treatment includes chemotherapy and radiation therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chondrosarcoma – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Chondrosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chondrosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chondrosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 13, 8 and 4 respectively. Similarly, the Universities portfolio in Phase I stages comprises 2 molecules, respectively.

Chondrosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Chondrosarcoma (Oncology).
• The pipeline guide reviews pipeline therapeutics for Chondrosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Chondrosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Chondrosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Chondrosarcoma (Oncology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Chondrosarcoma (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Chondrosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Chondrosarcoma - Overview
Chondrosarcoma - Therapeutics Development
Chondrosarcoma - Therapeutics Assessment
Chondrosarcoma - Companies Involved in Therapeutics Development
Chondrosarcoma - Drug Profiles
Chondrosarcoma - Dormant Projects
Chondrosarcoma - Discontinued Products
Chondrosarcoma - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Chondrosarcoma, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Chondrosarcoma - Pipeline by Aadi Bioscience Inc, H1 2020
Chondrosarcoma - Pipeline by Acrotech Biopharma LLC, H1 2020
Chondrosarcoma - Pipeline by Advenchen Laboratories LLC, H1 2020
Chondrosarcoma - Dormant Projects, H1 2020
Chondrosarcoma - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Chondrosarcoma, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Aadi Bioscience Inc
Acrotech Biopharma LLC
Advenchen Laboratories LLC
Agios Pharmaceuticals Inc
Alkermes Plc
Astex Pharmaceuticals Inc
Atlanthera
Bayer AG
BioMed Valley Discoveries Inc
Daiichi Sankyo Co Ltd
ENB Therapeutics LLC
Epizyme Inc
Forma Therapeutics Inc
Horizon Therapeutics Plc
Idera Pharmaceuticals Inc
ImmunityBio Inc
Karyopharm Therapeutics Inc
Merck & Co Inc
Nanode Therapeutics Inc
Nektar Therapeutics
Novartis AG
Ono Pharmaceutical Co Ltd
Pfizer Inc
Pharma Mar SA